1. Home
  2. SGMT

as 05-09-2025 12:43pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Nasdaq

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Founded: 2006 Country:
United States
United States
Employees: N/A City: SAN MATEO
Market Cap: 71.2M IPO Year: 2023
Target Price: $25.67 AVG Volume (30 days): 553.0K
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.78 EPS Growth: N/A
52 Week Low/High: $1.73 - $7.38 Next Earning Date: 05-08-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

SGMT Daily Stock ML Predictions

Share on Social Networks: